發(fā)布時間：2018-01-06 23:32

  本文關(guān)鍵詞：DPP-4抑制劑聯(lián)合二甲雙胍治療T2DM的短期效果及長期藥物經(jīng)濟學(xué)評價　出處：《山東大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 二甲雙胍 DPP-4抑制劑 Meta分析 藥物經(jīng)濟學(xué) Markov模型 成本-效用分析

【摘要】：目的糖尿病是全世界人民共同面臨的重大公共衛(wèi)生問題,其中約900%0～95%為2型糖尿病(type 2 diabetes mellitus, T2DM)患者。T2DM是一種慢性疾病,病程較長且血糖需要長期維持在一個較好的水平上,如果血糖控制不佳會引起嚴重的大血管及微血管并發(fā)癥,不僅影響患者生活質(zhì)量,還給患者及社會帶來巨大經(jīng)濟負擔(dān)。因此,臨床不僅需要療效顯著更需要經(jīng)濟性好的藥物用于糖尿病的治療和并發(fā)癥的預(yù)防。目前臨床常用的降糖藥物有很多,其中二甲雙胍是T2DM患者控制血糖的一線用藥和聯(lián)合用藥中的基本藥物,然而二甲雙胍在用藥初期療效顯著,隨著病情進展往往需要與第二種降糖藥物聯(lián)合使用。如何選擇與二甲雙胍聯(lián)合應(yīng)用的降糖藥物是一直以來我們不斷探討的問題。英國前瞻性糖尿病研究(United Kingdom Prospective Diabetes study, UKPDS)結(jié)果顯示,無論采用哪種聯(lián)合方式,隨著糖尿病進展,胰島細胞功能都會出現(xiàn)進行性衰退,最終導(dǎo)致血糖控制不佳,因此保護胰島細胞功能、延緩其衰退進度是新治療方案的一個重要靶點。二肽基肽酶-4(dipeptidyl peptidase-4, DPP-4)抑制劑的出現(xiàn)給患者帶來希望,其不僅能提高胰高血糖素樣肽-1 (glucagonlike peptide-1, GLP-1)和葡萄糖依賴性促胰島素釋放多肽(glucose-dependent insulinotropic polypeptide, GIP)的水平及其活性,還能保護胰島p細胞,從而延緩并發(fā)癥的發(fā)生和發(fā)展。其中,DPP-4抑制劑與二甲雙胍聯(lián)合治療手段也受到越來越多臨床醫(yī)生的青睞。隨著DPP-4抑制劑在臨床推廣使用,為能更好的指導(dǎo)臨床實踐,有必要全面了解DPP-4抑制劑聯(lián)合二甲雙胍的治療效果及安全性。因此,本課題首先通過Meta分析全面、系統(tǒng)地評價了與二甲雙胍相比,DPP-4抑制劑聯(lián)合二甲雙胍的短期治療效果及各種不良反應(yīng)的發(fā)生情況,同時鑒于亞洲人和高加索人人口統(tǒng)計學(xué)的差異,比較了兩個人種之間兩種用藥方案差異的不同。我國藥物經(jīng)濟學(xué)起步較晚,目前我國糖尿病領(lǐng)域多數(shù)藥物經(jīng)濟學(xué)研究方法單一且對治療方案僅進行了短期經(jīng)濟學(xué)評價。為進一步研究治療方案的長期經(jīng)濟性,本課題從社會角度出發(fā),在Meta分析基礎(chǔ)上,采用藥物經(jīng)濟學(xué)中研究較成熟的模型法,根據(jù)T2DM自然轉(zhuǎn)歸過程,建立Markov模型,進一步模擬DPP-4抑制劑聯(lián)合二甲雙胍治療T2DM 30年的成本及效用,從長期角度評價該聯(lián)合治療方案的療效和經(jīng)濟性,以期促進合理用藥,降低患者和社會的經(jīng)濟負擔(dān)。方法1 Meta分析檢索Medline (pubmed)數(shù)據(jù)庫、臨床試驗網(wǎng)站(www.clinicals.gov)及相關(guān)文獻的參考文獻列表,納入符合標準的隨機對照試驗,提取所需要的糖化血紅蛋白(glycosylated hemoglobin A1c, HbA1c)、空腹血糖(fasting plasma glucose, FPG)、體重、穩(wěn)態(tài)β細胞功能指數(shù)(homeostasis model assessment of β-cell function index, HOMA-β)、穩(wěn)態(tài)模型胰島素抵抗指數(shù)(homeostasis model assessment of insulin resistance index, HOMA-IR)、總膽固醇(total cholesterol, TC)、低密度脂蛋白膽固醇(low-density lipoprotein cholesterol,LDL-C)、甘油三酯(triglycerides, TG)、高密度脂蛋白膽固醇(high-density lipoprotein cholesterol, HDL-C)等效果數(shù)據(jù)及低血糖、胃腸道副反應(yīng)、胰腺炎等不良反應(yīng)數(shù)據(jù),應(yīng)用Review Manager (RevMan) 5.3統(tǒng)計分析合并提取的數(shù)據(jù)。2亞洲人和高加索人之間的比較應(yīng)用SPSS19軟件,比較與單用二甲雙胍相比,DPP-4抑制劑聯(lián)合二甲雙胍治療效果在亞洲人和高加索人之間的差異。3 DPP-4抑制劑聯(lián)合二甲雙胍的長期藥物經(jīng)濟學(xué)評價3.1 Markov模型的建立根據(jù)T2DM的自然轉(zhuǎn)歸過程,建立糖尿病無并發(fā)、糖尿病有并發(fā)癥及死亡的Markov模型狀態(tài),以1年為1個Markov周期,結(jié)合Meta分析及文獻研究獲得模型所需要的轉(zhuǎn)移概率、成本及效用值,模擬兩種方案治療30年所需要的成本及所獲的質(zhì)量調(diào)整生命年(Quality-adjusted Life Years, QALYs),從而進行長期的藥物經(jīng)濟學(xué)評價。3.2模型分析運用Markov模型進行回乘分析、隊列模擬獲得兩種治療方案所需要的成本及效用數(shù)據(jù),通過增量成本效用比(incremental cost-utility ratio, ICUR)評價DPP-4抑制劑聯(lián)合二甲雙胍治療的長期經(jīng)濟性,同時對成本、效用值及貼現(xiàn)率進行敏感度分析,評價模型的穩(wěn)定性。結(jié)果1 Meta分析根據(jù)納入和排除標準,共納入27篇隨機對照試驗,涉及患者10089名,其中DPP-4抑制劑聯(lián)合二甲雙胍組5569名,二甲雙胍單藥治療組4520名。與單用二甲雙胍相比,DPP-4抑制劑聯(lián)合二甲雙胍能顯著降低HbA1c-0.61%(-0.69 to-0.52, p0.00001)、FPG-1.10 mmol/1 (-1.29 to-0.92, p0.00001)和TG-0.21 mmol/1 (-0.33 to-0.10, p=0.0002)的水平,并能降低TC-0.11 mmol/1 (-0.20 to-0.02, p=0.02、HOMA-IR-0.19 (-0.36 to-0.02, p=0.03)和胃腸道副作用RR 0.88 (0.79 to 0.98, p=0.02)的發(fā)生率,同時顯著增加HOMA-β 8.86 (7.4 to 10.32, p0.00001)。對體重、LDL-C、HDL-C、胰腺炎及低血糖等不良反應(yīng)的影響,兩組之間沒有顯著性差異(p0.05)。敏感性分析結(jié)果示不同效應(yīng)模型的結(jié)果一致,模型穩(wěn)定性較好。2亞洲人和高加索人之間的比較納入的27篇隨機對照試驗中4篇文獻主要研究人群是亞洲人,23篇文獻主要研究高加索人。與二甲雙胍單劑量組相比,聯(lián)合用藥后,在HbA1c、FPG、體重和HOMA-IR方面,亞洲人和高加索人之間沒有顯著性差異,分別為-0.05%(-0.30 to 0.20, p=0.69)、0.17 mmol/1(-0.52 to 0.85,p=0.62)、-0.15kg (-0.64 to 0.35,p=0.53)和0.27(-0.98 to 1.53,p=0.64),而亞洲人HOMA-P的改善低于高加索人-5.79(-10.26 to-1.32,p=0.01)。3藥物經(jīng)濟學(xué)評價結(jié)果通過回乘分析得出五種DPP-4抑制劑聯(lián)合二甲雙胍的成本效用比分別為：西格列汀+二甲雙胍10713.41元/QALY、沙格列汀+二甲雙胍11261.50元/QALY、維格列汀+二甲雙胍11001.28元/QALY、格列汀+二甲雙胍11169.58元/QALY、阿格列汀+二甲雙胍10815.48元/QALY,由此看出西格列汀聯(lián)合二甲雙胍治療最具成本效用。對西格列汀+二甲雙胍治療組和二甲雙胍單藥治療組分別進行隊列模擬,結(jié)果顯示假設(shè)進入隊列的人群共1000人,與二甲雙胍治療組相比,西格列汀+二甲雙胍的治療挽救了53名患者的生命。成本效用分析顯示,3%的貼現(xiàn)率下西格列汀+二甲雙胍聯(lián)合治療糖尿病30年所需成本為157808.48元,與二甲雙胍組相比,增量成本為37533.14元,QALY為14.73年,比二甲雙胍治療組延長0.53年,ICUR為70817.24元/QALY,低于WHO推薦的閾值標準(3GDP),該聯(lián)合治療方案具有成本效用。敏感度分析結(jié)果顯示,當(dāng)各參數(shù)在設(shè)定范圍內(nèi)變化時不會影響模型結(jié)論。結(jié)論綜上所述,本課題系統(tǒng)、全面的評價了DPP-4抑制劑聯(lián)合二甲雙胍治療T2DM的短期效果和安全性,為臨床合理用藥提供了一定依據(jù)；運用Markov模型模擬該聯(lián)合方案治療30年的成本及效果,彌補了該領(lǐng)域研究數(shù)據(jù)不足的缺陷,綜合評價治療方案的健康產(chǎn)出和經(jīng)濟性,能在一定程度上提高患者生命質(zhì)量,減輕患者和社會的經(jīng)濟負擔(dān)。
[Abstract]:Objective: diabetes is a major public health problem facing the people of the world, which is about 900%0 ~ 95% for type 2 diabetes (type diabetes 2 mellitus, T2DM).T2DM patients is a chronic disease, longer duration and blood glucose to maintain long-term at a higher level, if poor glycemic control may cause serious vascular and microvascular complications, not only affects the quality of life of patients, to patients and society bring huge economic burden. Therefore, the clinical curative effect not only need more drugs and good economy for the prevention of diabetes treatment and complications. At present there are many commonly used medications, including metformin is the basic control of blood glucose in patients with T2DM first-line treatment and combined medication, but metformin efficacy in initial medication significantly, with the progression of the disease often need to combine with second kinds of hypoglycemic drugs Use. How to choose antidiabetic drugs combined with metformin as we continue to explore the problem. Since the UK Prospective Diabetes Study (United Kingdom Prospective Diabetes study, UKPDS) the results showed that either the United way, with the development of diabetes, islet cell function appears to decline, resulting in poor glycemic control therefore, the protection of islet cell function, delay the decline of progress is an important target for new therapies. Two peptide peptidase -4 (dipeptidyl peptidase-4 DPP-4) inhibitors appears to the patients hope, it can not only improve the glucagon like peptide -1 (glucagonlike peptide-1 GLP-1) and Glucose dependent insulinotropic insulin releasing polypeptide (glucose-dependent insulinotropic, polypeptide, GIP) and the level of activity, but also to protect the islet P cells, thus delaying the complications. Health and development. Among them, the DPP-4 inhibitor and metformin treatment has attracted more and more attention. Clinicians with the use of DPP-4 inhibitors in clinical practice, to guide clinical practice better, it is necessary to fully understand the efficacy and safety of DPP-4 inhibitors combined with metformin. Therefore, this paper first through Meta analysis comprehensively, systematically the evaluation compared with metformin and DPP-4 inhibitors combined with metformin treatment effect and short-term adverse reaction conditions, at the same time, in view of the differences between Asian and Caucasian population statistics, comparison between the two races of two regimens for different drugs. Economics in China started late, the current single research methods the majority of our field of diabetes drug economics and the treatment only short-term economic evaluation. For the further study of treatment regimens The long-term economy, from the social point of view, based on the Meta analysis, the model research of mature drug economics, according to the T2DM natural history process, establish the Markov model, the cost and utility of further simulation of DPP-4 inhibitors combined with metformin in the treatment of T2DM for 30 years, and the economic evaluation of the efficacy of combination therapy in the long-term the angle, in order to promote the rational use of drugs, reduce the financial burden of patients and society. Methods 1 Meta Medline (PubMed) database retrieval analysis, clinical trial site (www.clinicals.gov) and the reference lists of relevant literature, randomized controlled trials with standard, glycosylated hemoglobin extract the need (glycosylated hemoglobin, A1c, HbA1c) fasting blood glucose (fasting plasma, glucose, FPG), body weight, stable beta cell function index (homeostasis model assessment of -cell function index HO beta. MA- beta), HOMA IR (homeostasis model assessment of insulin resistance index, HOMA-IR), total cholesterol (total, cholesterol, TC), low density lipoprotein cholesterol (low-density lipoprotein, cholesterol, LDL-C), triglycerides (triglycerides, TG), high density lipoprotein cholesterol (high-density lipoprotein cholesterol, HDL-C) etc. data and hypoglycemia, gastrointestinal side effects, pancreatitis and other adverse reactions, the application of Review Manager (RevMan) 5.3 statistical analysis with.2 data extraction between Asian and Caucasian compared with SPSS19 software, compared with the single metformin compared to long-term drug treatment effect of metformin combined with DPP-4 inhibitor economic differences between Asian and Caucasian.3 DPP-4 the 3.1 inhibitors combined with metformin Markov model is established according to T2DM self evaluation The transfer process, the establishment of diabetic without concurrent, diabetes complications and death Markov model state to 1 years for the 1 Markov cycle, combined with the analysis and literature research Meta transfer probability model is needed, the cost and utility value, simulation of two therapeutic schemes for 30 years required by quality and cost adjusted life year (Quality-adjusted Life Years, QALYs), so as to carry out the pharmacoeconomic evaluation of long-term.3.2 model analysis using Markov model to take the analysis, cost utility and the number of queue simulation of two kinds of treatment according to the need, through the incremental cost utility ratio (incremental cost-utility ratio, ICUR) long-term economic evaluation of DPP-4 inhibitors combined with at the same time of metformin treatment and cost sensitivity analysis of utility value and the discount rate, the stability evaluation model. The results of 1 Meta analysis according to the inclusion and exclusion criteria, 27 randomized controlled trials were included, involving 10089 patients, of which 5569 DPP-4 inhibitors combined with metformin group, metformin monotherapy group was 4520. Compared with metformin alone, DPP-4 inhibitors combined with metformin can significantly reduce the HbA1c-0.61% (-0.69 to-0.52 p0.00001), FPG-1.10 mmol/1 (-1.29 to-0.92, p0.00001 TG-0.21 and mmol/1 (-0.33) to-0.10, p=0.0002) level, and can reduce the TC-0.11 mmol/1 -0.20 (to-0.02, p=0.02, HOMA-IR-0.19 (-0.36 to-0.02 p=0.03) and gastrointestinal side effects of RR 0.88 (0.79 to 0.98, p=0.02) and a significant increase in the incidence of HOMA- beta 8.86 (7.4 to 10.32, p0.00001). The body weight, LDL-C, HDL-C. The adverse effect of pancreatitis and hypoglycemia, there is no significant difference between the two groups (P0.05). The sensitivity analysis results showed different effect model results, better stability of.2 Asian model And the comparison between Caucasians included 27 randomized controlled trials in 4 papers mainly study population are Asians, 23 papers mainly study Caucasians. Compared with the single dose metformin group, in combination, HbA1c, FPG, weight and HOMA-IR, there was no significant difference between Asian and Caucasus, respectively, -0.05% (-0.30 to 0.20, p=0.69), 0.17 mmol/1 (-0.52 to 0.85, p=0.62), -0.15kg (-0.64 to 0.35, p=0.53) and 0.27 (-0.98 to 1.53, p=0.64), and HOMA-P significantly lower than Caucasian Asians -5.79 (-10.26 to-1.32, p=0.01.3) through the results of pharmacoeconomic evaluation to take out five kinds of cost utility analysis DPP-4 inhibitors combined with metformin respectively than sitagliptin plus metformin for 10713.41 yuan /QALY, 11261.50 yuan /QALY Shah Glenn Dean + metformin and vildagliptin metformin + two 11001.28 yuan /QALY, Glenn + two armor Biguanide 11169.58 yuan /QALY, Agger 4 + metformin 10815.48 yuan /QALY, from that of sitagliptin and metformin in treatment of the most cost utility. The sitagliptin plus metformin treatment group and metformin group were the cohort simulation, results show that entering the queue among 1000 people, compared with metformin treatment group, treatment sitagliptin plus metformin 53 saved the lives of patients. The cost utility analysis showed that 3% of the discount rate of sitagliptin and metformin in treatment of diabetes for 30 years the cost of 157808.48 yuan, compared with metformin group, the incremental cost is 37533.14 yuan, QALY for 14.73 years, 0.53 years longer than the metformin treatment group ICUR, 70817.24 yuan /QALY, WHO lower than the recommended threshold standard (3GDP), the combination therapy has cost effectiveness. The sensitivity analysis results show that when the parameters in the set range Within the changes will not affect the model conclusions. In conclusion, this paper systematically, comprehensively evaluate the short-term efficacy and safety of DPP-4 inhibitors combined with metformin in the treatment of T2DM, provide a basis for clinical rational use of drugs; the cost and effect of applying Markov model to simulate the combined treatment plan for 30 years, to make up for deficiencies in the research in the field of data the lack of health outcomes and economic comprehensive evaluation of treatment, can improve the quality of life of patients to a certain extent, reduce the financial burden of patients and society.

【學(xué)位授予單位】：山東大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R587.1

【相似文獻】

相關(guān)期刊論文 前10條

1 宋小明,曹義福,蔡興榮;加工廢舊鐵桶引起的急性硫酸二甲脂中毒[J];職業(yè)醫(yī)學(xué);1985年05期

2 陳洪興;硫酸二甲脂中毒17例報告[J];遼寧醫(yī)學(xué)雜志;1996年03期

3 王家治;鞏固提高“二甲”醫(yī)院成果的對策[J];廠礦醫(yī)藥衛(wèi)生;1997年03期

4 張叔良;;Ⅸ-18標|dXW假漆的方法[J];藥學(xué)文摘;1958年03期

5 黃平;降糖益腎方合二甲雙瓜治療2型糖尿病50例[J];浙江中醫(yī)學(xué)院學(xué)報;2004年04期

6 余約軍;;二甲牛地湯治療重癥血小板減少癥二則[J];浙江中醫(yī)雜志;2010年01期

7 米玉華;硫酸二甲脂引起廣泛皮膚燒傷的護理[J];河南醫(yī)科大學(xué)學(xué)報;1995年04期

8 夏旭光;尹崢;;7-二氟亞甲基-5,4’-二甲烷氧基異黃酮對高糖損傷的猴視網(wǎng)膜血管內(nèi)皮細胞的保護作用[J];眼科新進展;2008年02期

9 石榮顯，鄧小群，趙永林;二甲唑的合成[J];中國醫(yī)藥工業(yè)雜志;1994年08期

10 劉厚德;淺談創(chuàng)建“二甲”婦保院的幾點體會[J];江蘇衛(wèi)生事業(yè)管理;2005年01期

相關(guān)會議論文 前10條

1 郭勇;;搶救一例二甲硫酯中毒的體會[A];第十一次全國急診醫(yī)學(xué)學(xué)術(shù)會議暨中華醫(yī)學(xué)會急診醫(yī)學(xué)分會成立二十周年慶典論文匯編[C];2006年

2 邱明琪;;關(guān)于二甲雙胍降糖以外的療效[A];江西省中西醫(yī)結(jié)合學(xué)會內(nèi)分泌專業(yè)委員會第二次學(xué)術(shù)會議、內(nèi)分泌與代謝性疾病中西醫(yī)結(jié)合診治新進展學(xué)習(xí)班資料匯編[C];2013年

3 高曉東;胡必杰;崔揚文;孫偉;沈燕;;上海市二甲以上醫(yī)院環(huán)境清潔消毒及監(jiān)測現(xiàn)狀調(diào)查[A];中華醫(yī)學(xué)會第七次全國中青年檢驗醫(yī)學(xué)學(xué)術(shù)會議論文匯編[C];2012年

4 鄭驕陽;陸斌;鄒俊杰;陳向芳;石勇銓;劉志民;;鹽酸二甲雙胍緩釋片治療2型糖尿病的療效及安全性研究[A];2008內(nèi)分泌代謝性疾病系列研討會暨中青年英文論壇論文匯編[C];2008年

5 徐書杭;陳國芳;劉超;;二甲雙胍的降糖外作用[A];5TH全國中西醫(yī)結(jié)合內(nèi)分泌代謝病學(xué)術(shù)大會暨糖尿病論壇論文集[C];2012年

6 張丹丹;沈鶯;劉芳;;性激素對2型糖尿病患者體內(nèi)二甲雙胍代謝以及血乳酸的影響[A];中華醫(yī)學(xué)會第十一次全國內(nèi)分泌學(xué)學(xué)術(shù)會議論文匯編[C];2012年

7 賴曉陽;高慧;;左旋甲狀腺素片聯(lián)合二甲雙胍對肥胖伴多囊卵巢綜合征的療效觀察[A];中華醫(yī)學(xué)會第二屆糖尿病及性腺疾病學(xué)術(shù)會議論文集[C];2012年

8 王增;余勤;梁茂植;向瑾;南峰;秦永平;;HPLC-MS/MS法測定人血漿中二甲啡烷濃度[A];第十三次全國臨床藥理學(xué)學(xué)術(shù)大會論文匯編[C];2012年

9 徐晶晶;林金芳;;二甲雙胍治療青春期PCOS患者后各項胰島素敏感性指標變化之比較[A];第七次全國婦科內(nèi)分泌學(xué)術(shù)會議論文匯編[C];2013年

10 劉娟;張久星;田甜;;二甲雙胍與硝苯地平合用致低血糖1例[A];2012年全國醫(yī)院藥學(xué)學(xué)術(shù)年會暨第72屆世界藥學(xué)大會衛(wèi)星會論文集[C];2012年

相關(guān)重要報紙文章 前8條

1 苗瑞峰;全市實現(xiàn)縣(市、區(qū))級醫(yī)院“二甲”全覆蓋[N];忻州日報;2011年

2 張柏林;二甲雙胍緩釋劑效價比優(yōu)勢明顯[N];中國醫(yī)藥報;2011年

3 宋明;德昌縣人民醫(yī)院 創(chuàng)“二甲”促醫(yī)院發(fā)展[N];涼山日報(漢);2010年

4 周俊佳;省專家組對寧南縣醫(yī)院進行“二甲”等級評審[N];涼山日報(漢);2010年

5 本報記者 金鑫;我市“二甲”醫(yī)院年內(nèi)實現(xiàn)全覆蓋[N];寶雞日報;2011年

6 記者 張淑會;受援醫(yī)院3年全“達”二甲[N];河北日報;2009年

7 本報通訊員 周東華 本報記者 王克勇;咬定青山不放松[N];臺州日報;2006年

8 本報記者 白潔 通訊員 王耀宗;目標，，在奮斗中實現(xiàn)[N];鄂爾多斯日報;2008年

相關(guān)博士學(xué)位論文 前4條

1 汪東;二甲雙胍抑制膀胱癌細胞并增強順鉑化療敏感性及其機制的研究[D];重慶醫(yī)科大學(xué);2015年

2 廖云飛;二甲雙胍對2型糖尿病患者循環(huán)內(nèi)皮祖細胞的影響及機制研究[D];華中科技大學(xué);2009年

3 李央;PCOS胰島素抵抗風(fēng)險因子與二甲雙胍治療干預(yù)研究[D];復(fù)旦大學(xué);2007年

4 龔燕平;二甲雙胍在新診斷2型糖尿病患者中的應(yīng)用[D];中國人民解放軍軍醫(yī)進修學(xué)院;2010年

相關(guān)碩士學(xué)位論文 前10條

1 耿飛飛;二甲雙胍與胰島素治療妊娠期糖尿病的療效及安全性系統(tǒng)評價[D];新疆醫(yī)科大學(xué);2015年

2 安宏;降糖消渴顆粒聯(lián)合二甲雙胍對糖尿病小鼠糖脂代謝及GLP-1的影響[D];北京中醫(yī)藥大學(xué);2016年

3 鄧恬;二甲雙胍預(yù)處理對抗小鼠急性缺血性腦損傷的作用研究[D];浙江大學(xué);2016年

4 戴曉康;二甲雙胍對2型糖尿病患者尿炎癥因子排泄的影響[D];安徽醫(yī)科大學(xué);2016年

5 王雪;合并2型糖尿病的Ⅰ型子宮內(nèi)膜癌患者預(yù)后分析[D];山東大學(xué);2016年

6 郭娜;二甲雙胍抑制晚期糖基化終產(chǎn)物誘導(dǎo)的大腸癌細胞侵襲和上皮間質(zhì)轉(zhuǎn)化[D];山東大學(xué);2016年

7 李巖;GLP-1對比二甲雙胍對超重或肥胖患者減重療效和安全性的系統(tǒng)評價[D];廣西醫(yī)科大學(xué);2016年

8 高雯雯;DPP-4抑制劑聯(lián)合二甲雙胍治療T2DM的短期效果及長期藥物經(jīng)濟學(xué)評價[D];山東大學(xué);2016年

9 寧丹;二甲雙胍對他克莫司和雷帕霉素誘導(dǎo)的糖尿病的不同影響[D];延邊大學(xué);2016年

10 陳彬;二甲雙胍對子宮內(nèi)膜癌合并糖尿病患者治療作用的回顧性分析[D];山東大學(xué);2016年

本文編號：1390024